The Philippine Food and Drug Association says drugmaker Sanofi (SNY)  knew that its dengue fever vaccine was dangerous to people who had never had the disease, since in 2015, but failed to inform the government when it applied for drug approval in Singapore.

Sanofi's drug was approved on Dec. 22, 2015, but the company only advised of the vaccine's limitations in November 2017. 

The Philippine government suspended the school-based dengue fever immunization program in December 2017 after the French vaccine maker stated that the vaccine could cause more severe cases of dengue if administered to people who hadn't had the disease prior. 

The program ended up costing the Philippine government $67 million. More than 700,000 children ages 9 and above were given their first dose of the vaccine as of November 2017. 

A Philippine lawmaker estimated that 90% of patients who sought medical assistance at the drug's rollout turned out to be negative for the disease. 

Sanofi shares were rising in afternoon trading Monday, up 0.77% to $40.44. 

More from Stocks

Global Stocks Mixed as China GDP Slows, Brexit Uncertainty Hangs Over Europe

Global Stocks Mixed as China GDP Slows, Brexit Uncertainty Hangs Over Europe

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Why Bankrate's CFA Expects Two More Rate Hikes in 2019

Why Bankrate's CFA Expects Two More Rate Hikes in 2019

Norwegian Cruise Lines Could Be Docking With a Dividend in 2019

Norwegian Cruise Lines Could Be Docking With a Dividend in 2019

Why Sears is One of Jim Cramer's 'Finest Hours'

Why Sears is One of Jim Cramer's 'Finest Hours'